as 08-22-2025 4:00pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Founded: | 2018 | Country: | United States |
Employees: | N/A | City: | BRISBANE |
Market Cap: | 624.8M | IPO Year: | 2021 |
Target Price: | $27.86 | AVG Volume (30 days): | 2.1M |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.94 | EPS Growth: | N/A |
52 Week Low/High: | $5.63 - $16.76 | Next Earning Date: | 08-05-2025 |
Revenue: | $187,638,000 | Revenue Growth: | 2190.50% |
Revenue Growth (this year): | 16.42% | Revenue Growth (next year): | 47.52% |
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
GOBankingRates
3 months ago
GOBankingRates
3 months ago
GOBankingRates
3 months ago
Yahoo Finance
3 months ago
The Guardian
3 months ago
Yahoo Finance Video
3 months ago
Benzinga
3 months ago
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.